During the past decade, Unisanté, Centre universitaire de médecine générale et santé publique, Université de Lausanne conducted 21 clinical trials. In the 10-year time frame, 21 clinical trials started and 2 clinical trials were completed, i.e. on average, 9.5% percent of trials that started reached the finish line to date. In the past 5 years, 12 clinical trials started and 0 clinical trials were completed. i.e. 0% of trials that started reached the finish line.

Out of the total clinical trials conducted in "Unisanté, Centre universitaire de médecine générale et santé publique, Université de Lausanne" #1 sponsor was "University of Bern" with 10 trials, followed by "Center for Primary Care and Public Health (Unisante), University of Lausanne, Switzerland" with 8 trials sponsored, "Emergex Vaccines Holding Ltd." with 2 trials sponsored, "Pfizer" with 2 trials sponsored and "Amgen" with 2 trials sponsored. Other sponsors include -2 different institutions and companies that sponsored additional 8 trials in total.

In terms of collaborators to trials, out of the total clinical trials conducted in "Unisanté, Centre universitaire de médecine générale et santé publique, Université de Lausanne" #1 collaborator was "Swiss National Science Foundation" with 11 trials as a collaborator, "University of Lausanne" with 11 trials as a collaborator, "University of Geneva, Switzerland" with 10 trials as a collaborator, "State Hospital, St. Gallen" with 9 trials as a collaborator and "University of Zurich" with 9 trials as a collaborator. Other collaborators include 31 different institutions and companies that were collaborators in the rest 19 trials.

According to Clinical.Site data, the most researched conditions in "Unisanté, Centre universitaire de médecine générale et santé publique, Université de Lausanne" are "Smoking Cessation" (11 trials), "COVID-19" (3 trials), "Atherosclerotic Cardiovascular Disease" (2 trials), "Cardiovascular Disease" (2 trials) and "Cardiovascular Diseases" (2 trials). Many other conditions were trialed in "Unisanté, Centre universitaire de médecine générale et santé publique, Université de Lausanne" in a lesser frequency.

Most popular intervention types in "Unisanté, Centre universitaire de médecine générale et santé publique, Université de Lausanne" are "Other" (14 trials), "Drug" (4 trials), "Behavioral" (2 trials), "Biological" (2 trials) and "Diagnostic Test" (1 trials). Other intervention types were less common.

The name of intervention was led by "ENDS (vaporizer/e-cig) and smoking cessation counseling" (9 trials), "Smoking cessation counseling" (9 trials), "Placebo" (2 trials), "bococizumab (PF-04950615)" (2 trials) and "0.9% sodium chloride solution" (1 trials). Other intervention names were less common.

The vast majority of trials in "Unisanté, Centre universitaire de médecine générale et santé publique, Université de Lausanne" are 24 trials for "All" genders and 2 trials for "Female" genders.

Currently, there are NaN active trials in "Unisanté, Centre universitaire de médecine générale et santé publique, Université de Lausanne". undefined are not yet recruiting, 3 are recruiting, 10 are Active, not recruiting, and undefined are Enrolling by invitation. In total, there were 8 completed trials in Unisanté, Centre universitaire de médecine générale et santé publique, Université de Lausanne, 1 suspended trials, and 3 terminated clinical trials to date.

Out of the total trials that were conducted in Unisanté, Centre universitaire de médecine générale et santé publique, Université de Lausanne, 2 "Phase 1" clinical trials were conducted, 1 "Phase 2" clinical trials and 3 "Phase 3" clinical trials were conducted as well. "Phase 4" trials included 1 trials, and there were also 15 trials that are defined as “Not Applicable".